Search results: (10000)
News One Step Closer to Understanding the Placebo Effect in Pain Treatment
Neuroscientists from the USA appear to have advanced our understanding of the placebo effect in pain relief. Their findings, recently published in Nature, open the possibility of influencing the described pain control pathway using drugs or neurostimulation.
News CASE STUDY: Surgical Procedure in an Adolescent Patient with Severe Hemophilia A on Emicizumab Prophylaxis
This case study is narrated by MUDr. Bohumír Blažek from the Clinic of Pediatric Medicine at LF OU and FN Ostrava. The patient is a 17-year-old boy with severe hemophilia A. Several months prior to the procedure under discussion, he was switched from prophylactic factor VIII administration to emicizumab prophylaxis. Subsequently, an extraction of all four molars was planned for orthodontic reasons. The case study describes the hematologist's approach to the procedure and the subsequent healing process.
News Effect of Administering Ferric Carboxymaltose on Quality of Life in Heart Failure Patients
The quality of life in patients with heart failure is significantly reduced. The concurrent occurrence of iron deficiency further exacerbates this situation. The AFFIRM-AHF study evaluated the impact of intravenous administration of ferric carboxymaltose on health-related quality of life (HRQoL) in patients with heart failure who also suffered from iron deficiency.
News Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were observed between two extended half-life factors.
News Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple pharmacokinetic protocol for patients with hemophilia A.
News Efficacy and Safety of the Combination of Telmisartan and Amlodipine with Hydrochlorothiazide in the Treatment of Hypertension
The aim of the study by Korean authors was to evaluate the efficacy and tolerability of the triple combination of telmisartan/amlodipine + hydrochlorothiazide (TAH) compared to the combination of telmisartan/amlodipine (TA) alone in patients with essential hypertension who did not respond sufficiently to a 4-week treatment with TA.
News In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role
The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a time of rapid development of new treatment options. Patient priorities and their perception of treatment can, alongside the assessment of the efficacy or toxicity of a modality, also influence decisions about the therapeutic strategy.
News Anticoagulation Therapy in Patients on ECMO During the COVID-19 Pandemic
In the past 2 years, the use of extracorporeal membrane oxygenation (ECMO) in intensive care units (ICU) has increased in connection with the treatment of severe COVID-19 pneumonia. Dr. Pilar Marcos Neira from the ICU at Germans Trias i Pujol Hospital in Barcelona has compiled a summary of updated knowledge on anticoagulation therapy in these patients.
News Quo vadis, erdostein? Or the current and future potential of erdosteine in practice
Erdosteine has a well-established place in the therapy of acute respiratory diseases in children. Its mucolytic and antibacterial properties are very well documented. Recently, research has focused primarily on the anti-inflammatory and antioxidant effects of this molecule. Attention is also being paid to its antiviral potential. How does it stand in this regard?
News What is the effectiveness of levodropropizine in the treatment of children's cough?
Levodropropizine represents an effective and safe option for the treatment of acute irritating cough in children. How does it compare to dropropizine and commonly used centrally acting antitussives?
News Fresh from ASH 2021: Promising results of the combination of azacitidine with venetoclax and magrolimab in the treatment of AML
Dr. Naval Daver and his colleagues from the Anderson Cancer Center in Houston presented an oral report during the December congress of the American Society of Hematology (ASH 2021) about a phase Ib/II study that evaluated the effects of the combination of azacitidine (AZA) + venetoclax (VEN) + magrolimab (magro) in various types of patients with acute myeloid leukemia (AML) – newly diagnosed in older or unfit individuals, high-risk, or relapsed/refractory cases (R/R AML).
News Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC
A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors – brigatinib, followed by lorlatinib – in real-world clinical practice.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma
At the 12th International Symposium on Hodgkin Lymphoma (ISHL), held in October 2022 in Cologne, results of a Czech study evaluating the efficacy and safety of consolidation therapy with brentuximab vedotin in patients after autologous stem cell transplantation were presented.
News Inclisiran − a new addition to the arsenal of dyslipidemia treatment
At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule − inclisiran were presented at the Novartis company symposium.